Panel discounts ground water contamination by Fort Detrick

Despite the fact that the lymphoma rate appears to be higher among residents who live in the community surrounding Fort Detrick in Frederick County, Maryland, than the statewide average, an independent panel of scientists says that it's not possible to determine whether the toxic pollution is to be blamed or not.

The issue turns on whether the tons of carcinogenic chemicals buried decades ago at Fort Detrick tainted the ground water and thus caused several negative health effects, including cancers such as lymphomas.

One study put out by the U.S. Agency for Toxic Substances and Disease Registry claimed that the tainted ground water was "unlikely to have produced any harmful health effects, including cancer."

Furthermore, reviewers from the National Research Council endorsed a study by the state of Maryland and Frederick County health departments which found no evidence of cancer clusters in the area.

Activists whole-heartedly disagree and will continue to fight for further investigation.

For extra coverage, please see The Baltimore Sun.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap